Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

352

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2029

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Docetaxel, nedaplatin, fluorouracil

Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.

DRUG

Docetaxel, cisplatin, fluorouracil

Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Cisplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.

DRUG

Nedaplatin

Concurrent chemotherapy. Nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.

DRUG

Cisplatin

Concurrent chemotherapy. Cisplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.

RADIATION

Intensity modulated-radiotherapy

Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.

Trial Locations (1)

510095

RECRUITING

Department of radiotherapy(Section 5),Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

OTHER

NCT04437329 - Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter